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We appreciate Ms Cohain’s interest in our manuscript and
concerns regarding the association between oxytocin use and
uterine rupture.1 Unfortunately, oxytocin use was only one
obstetric covariate and not our main focus. In addition, the
facts presented in Ms Cohain’s letter are incorrect; 4 women
with primary uterine rupture were neither induced nor
received oxytocin augmentation. The claim that “the un-
scarred uterus that is not artiﬁcially forced to contract, will not
contract so hard as to explode itself” should not, as the ma-
jority of situations in medicine and in obstetrics, be considered
absolute. We speculate that underlying undiagnosed connec-
tive tissue aberrations or genetic factors may have inﬂuenced
the development of uterine rupture in these 4 women. Un-
fortunately, our study design precludes an investigation of
causation.
The incidence of oxytocin use was greater in unscarred
cases (80% vs 37%, odds ratio 6.7, P < .001). This statistic
shows an association between oxytocin use in unscarred
uterine ruptures compared with scarred uterine ruptures but
does not prove causation. Our comment that the increased
rate of oxytocin use in primary uterine rupture cases “likely
reﬂect differences in provider management among women670 American Journal of Obstetrics & Gynecology MAY 2016with a scarred uterus” is our acknowledgement that associa-
tion and causation are separate and that all statistics must
be interpreted within clinical practice. Furthermore, this
statement reﬂects provider differences in the management
of women with and without a uterine scar, because many
obstetric providers minimize the use of labor induction
and oxytocin augmentation in the setting of a previous
uterine scar. The use of oxytocin may increase the risk for
primary uterine rupture, because it is a known risk factor
for rupture of the scarred uterus.2
Ms Cohain references Tversky and Kahneman’s “Belief
in the Law of Small Numbers” to question our results and
interpretation.3 We acknowledge the (thankfully) few primary
uterine rupture cases as a study limitation. Tversky
and Kahneman caution the observer from making assump-
tions from small numbers (although they never deﬁne what
constitutes a “small number”—in their paper, 20 subjects
is seen as a reasonable sample size). As physician scientists,
however, we must make do with clinical realities.
In conclusion, we urge all clinicians providing obstetric
care to women to recognize that risk factors and associations
are powerful tools but they are not absolutes. Although
extremely rare, devastating obstetric outcomes such as pri-
mary uterine rupture (even in the labor absence of induction
or augmentation) may occur in any gravida, with potentially
catastrophic morbidity and mortality. -
Karen Jayne Gibbins, MD
University of Utah Health Sciences and Intermountain Healthcare
karen.gibbins@hsc.utah.edu
Tracy A. Manuck, MD
University of North Carolina at Chapel Hill School of Medicine
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genetic variantsTO THE EDITORS: I read with great interest the article
by MacLennan et al1 on cerebral palsy (CP), in which the
authors provided a comprehensive outline of the varied
pathogenesis as well as associated clinical risk factors relevant
to the practicing clinician.I was, however, surprised to read that a strong emphasis
was not placed on the use of magnesium sulphate in reducing
the risk of CP. Although this was mentioned under the
“Interventions to prevent CP” subheading, it was limited to
a small paragraph, leaving potential readers saddened or
ajog.org Letters to the Editorsdiscouraged by the lack of therapeutic options available to
prevent such a disabling disorder. Again, under the “Future
clinical applications” subheading, the authors declared that
the long-term goal is the prevention of CP—with no mention
or any arguments made as to the future role of such therapy.
Since 2010, both the United States and Australasia have been
on the forefront in establishing national guidelines on the use
of magnesium sulphate for neuroprotection of very preterm
infants.2 As referenced by the authors, this was based on good-
quality randomized controlled trials and meta-analyses that
demonstrated its effectiveness. Although other countries such
as Canada have followed through, the United Kingdom
remained guarded and cited the large number needed to treat
for beneﬁt (as compared with antenatal administration of
corticosteroids to prevent respiratory distress syndrome) as 1
of the possible reservations.3 I appreciate that the available data
are limited for late-preterm and term infants, and hope that the
MAGENTA study4—an ongoing randomised controlled trial
assessing antenatal magnesium sulphate administration
between 30 and 34 weeks gestation—will provide further
evidence to support to such a policy.
The magnitude might be small, but antenatal administra-
tion of magnesium sulphate may be the greatest primary
preventive intervention that we obstetricians should practice
on a daily basis to prevent CP. -
Wei How Lim, MBBS
North West Regional Hospital
Burnie, Tasmania, Australia
weihowlim@gmail.com
The author reports no conﬂict of interest.
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We thank Dr Lim for his interest in our review of the
causes, pathways, and, in particular, the role of genetic
variants that may contribute to cerebral palsy.1 It was a big
topic, and with limited space we focused on causation and
the increasing evidence for genetic causation in many of the
cerebral palsies. We are very aware and supportive of the
admirable work in our department of Professor Caroline
Crowther’s team and many others on the use of magnesium
sulphate in very-preterm labor to help reduce slightly the
risk of cerebral palsy in this subgroup. We applaud this
clinical intervention. However, for major progress to be
made in reducing all types of cerebral palsy, we need to
conduct much more neurodevelopmental research extending
back to conception. -
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